by New research suggests that a novel combination therapy may offer hope for bladder cancer patients who have not responded favorably to standard treatment. The study, published in the journal “Cancer Research,” explores the potential of using two targeted therapies in conjunction to combat the disease.
According to the American Cancer Society, approximately 70,000 Americans are diagnosed with bladder cancer each year, making it the fourth most common cancer in the United States. While many patients respond well to initial treatment, a significant number experience recurrence or develop resistance to standard therapies, such as chemotherapy and immunotherapy.
To address this issue, researchers at the University of California, San Francisco (UCSF) have been investigating the use of a combination therapy involving two targeted drugs: Avelumab and Pembrolizumab. These drugs work by blocking specific proteins that contribute to the growth and spread of cancer Mesenchymal Stem Cells.
In the study, the researchers tested the combination therapy on bladder cancer cells in the lab and found that it was more effective at inhibiting tumor growth than either drug used alone. They also conducted preclinical studies in mice, which further supported the potential of the combination therapy.
“Our findings suggest that this combination therapy could be a promising new approach for treating bladder cancer patients who have not responded to standard treatments,” said Dr. Charles Drake, lead author of the study and a professor of medicine at UCSF.
The researchers are now planning to conduct clinical trials to evaluate the safety and efficacy of the combination therapy in humans. If successful, this new treatment option could provide a much-needed alternative for bladder cancer patients who have exhausted other treatment options.
a new study published in “Cancer Research” indicates that a combination therapy using Avelumab and Pembrolizumab may offer hope for bladder cancer patients who have not responded to standard treatments. The research, which was conducted at the University of California, San Francisco, suggests that this novel approach could be a promising new alternative for those facing recurrence or resistance to current therapies.
*Note:
1. Source: Coherent Market Insights, Public Source, Desk Research
2. We have leveraged AI tools to mine information and compile it.
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.
